{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01742533",
      "OrgStudyIdInfo": {
        "OrgStudyId": "BKCR-POF-1(Ⅰ)"
      },
      "Organization": {
        "OrgFullName": "Shenzhen Beike Bio-Technology Co., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure",
      "OfficialTitle": "A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Hormone Replacement Therapy in Patients With Premature Ovarian Failure"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2012",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 2012"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2013",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 2014",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "November 26, 2012",
      "StudyFirstSubmitQCDate": "December 2, 2012",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 5, 2012",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "December 2, 2012",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 5, 2012",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Shenzhen Beike Bio-Technology Co., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Premature ovarian failure (POF) refers the occurrence of amenorrhoea, elevated serum gonadotrophins and hypoestrogenism levels in female before the age of 40. It has important physical and psychological consequences/impact in those patients.\n\nPremature ovarian failure (POF) is currently managed by non-physiological sex steroid regimens which are inadequate at optimizing uterine characteristics.\n\nHuman umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy for POF.\n\nIn this study, the safety and efficacy of hUCMSCs and hCBMNCs transplantation combined with Hormone Replacement Therapy will be evaluated in patients with Premature Ovarian Failure. Participants will be followed for an expected average of 48 weeks."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Premature Ovarian Failure，"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Hormone Replacement Therapy，",
          "Premature Ovarian Failure，",
          "Stem Cell Therapy"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "40",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Group1 : HRT plus hUCMSCs treatment:",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: human umbilical cord mesenchymal stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group 2: HRT plus hCBMNCs and hUCMSCs therapy",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: hUCMSCs and hCBMNCs"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group3 : HRT plus hCBMNCs treatment:",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: human cord blood mononuclear cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Group 4:Hormone Replacement Therapy",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Hormone Replacement Therapy"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "human umbilical cord mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group1 : HRT plus hUCMSCs treatment:"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "hUCMSCs and hCBMNCs",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group 2: HRT plus hCBMNCs and hUCMSCs therapy"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "human cord blood mononuclear cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group3 : HRT plus hCBMNCs treatment:"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Hormone Replacement Therapy",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Group 4:Hormone Replacement Therapy"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Serum Level of follicle-stimulating hormone",
            "PrimaryOutcomeTimeFrame": "48 weeks after treatment"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Uterine and Ovary characteristics of B ultrasound， including Uterine/Ovarian size and Blood Flow",
            "SecondaryOutcomeTimeFrame": "48 weeks after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Modified Kupperman Score",
            "SecondaryOutcomeTimeFrame": "48 weeks after treatment"
          },
          {
            "SecondaryOutcomeMeasure": "Incidence of Adverse Events and Serious Adverse Events",
            "SecondaryOutcomeTimeFrame": "48 weeks after treatment"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nBetween age 18- 39 years, Female only.\nDiagnosed with Premature Ovarian Failure，and currently receiving Hormone Replacement Therapy;\nWilling to sign the Informed Consent Form.\n\nExclusion Criteria:\n\nFragile X chromosome.\npolycystic ovary syndrome.\nHIV+.\nAutoimmune disease, e.g. lupus erythematosus, multiple sclerosis.\nSevere pulmonary and hematological disease, malignancy or hypo-immunity.\nCurrently undertaking other treatment that may affect the safety/efficacy of stem cells.\nPregnancy or lactation\nEnrollment in other trials in the last 3 months. • Other criteria the investigator consider improper for inclusion.",
      "HealthyVolunteers": "No",
      "Gender": "Female",
      "MinimumAge": "18 Years",
      "MaximumAge": "39 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "FangMing Su, Master",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "86-755-25533018",
            "CentralContactEMail": "sfmlxq@163.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Shenzhen People's Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Shenzhen",
            "LocationState": "Guangdong",
            "LocationZip": "518020",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Fangming Su",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "86-755-25533018",
                  "LocationContactEMail": "sfmlxq@163.com"
                },
                {
                  "LocationContactName": "Fangming Su",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000047928",
            "ConditionMeshTerm": "Premature Birth"
          },
          {
            "ConditionMeshId": "D000016649",
            "ConditionMeshTerm": "Primary Ovarian Insufficiency"
          },
          {
            "ConditionMeshId": "D000008594",
            "ConditionMeshTerm": "Menopause, Premature"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007752",
            "ConditionAncestorTerm": "Obstetric Labor, Premature"
          },
          {
            "ConditionAncestorId": "D000007744",
            "ConditionAncestorTerm": "Obstetric Labor Complications"
          },
          {
            "ConditionAncestorId": "D000011248",
            "ConditionAncestorTerm": "Pregnancy Complications"
          },
          {
            "ConditionAncestorId": "D000010049",
            "ConditionAncestorTerm": "Ovarian Diseases"
          },
          {
            "ConditionAncestorId": "D000000291",
            "ConditionAncestorTerm": "Adnexal Diseases"
          },
          {
            "ConditionAncestorId": "D000006058",
            "ConditionAncestorTerm": "Gonadal Disorders"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M25022",
            "ConditionBrowseLeafName": "Premature Birth",
            "ConditionBrowseLeafAsFound": "Premature",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18172",
            "ConditionBrowseLeafName": "Primary Ovarian Insufficiency",
            "ConditionBrowseLeafAsFound": "Premature Ovarian Failure",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10729",
            "ConditionBrowseLeafName": "Menopause, Premature",
            "ConditionBrowseLeafAsFound": "Premature Ovarian Failure",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9924",
            "ConditionBrowseLeafName": "Obstetric Labor, Premature",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9916",
            "ConditionBrowseLeafName": "Obstetric Labor Complications",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13279",
            "ConditionBrowseLeafName": "Pregnancy Complications",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12124",
            "ConditionBrowseLeafName": "Ovarian Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M2795",
            "ConditionBrowseLeafName": "Adnexal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8315",
            "ConditionBrowseLeafName": "Gonadal Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T6036",
            "ConditionBrowseLeafName": "Menopause",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000006728",
            "InterventionMeshTerm": "Hormones"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000006730",
            "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M8941",
            "InterventionBrowseLeafName": "Hormones",
            "InterventionBrowseLeafAsFound": "Adolescents",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M8940",
            "InterventionBrowseLeafName": "Hormone Antagonists",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}